PAMP

Mechanism of Action

• Inhibits norepinephrine release from sympathetic nerve terminals, reducing peripheral vascular resistance (differs from adrenomedullin vasodilation mechanism)
• Directly relaxes vascular smooth muscle via a mechanism independent of NO and cAMP, possibly involving imidazoline receptor I1
• Suppresses cardiac hypertrophy: PAMP-12 and PAMP-20 inhibit angiotensin II-induced cardiomyocyte protein synthesis and hypertrophic gene expression
• Anti-apoptotic in cardiomyocytes: PAMP reduces ischemia/reperfusion-induced apoptosis via ERK1/2 activation
• PAMP plasma levels rise in parallel with adrenomedullin during sepsis, heart failure, and acute myocardial infarction

Research Findings

• PAMP infusion in anesthetized cats and dogs produced dose-dependent hypotension more sustained than adrenomedullin at equivalent doses
• PAMP-12 (shorter bioactive fragment) is the most potent fragment in vasodilatory and hypotensive assays
• PAMP plasma levels elevated in patients with essential hypertension and heart failure; correlates with BNP and adrenomedullin
• Cardiac-specific PAMP overexpression in mice reduced pressure overload-induced hypertrophy and preserved ejection fraction
• MR-proADM (midregional proadrenomedullin) clinical assay measures both AM and PAMP region collectively as cardiovascular biomarker

Research Protocols

• Vasodilation: 1-100 pmol/kg/min IV infusion in anesthetized cats; blood pressure measured by direct arterial cannula
• Anti-hypertrophic: 1-100 nM PAMP on neonatal rat cardiomyocytes treated with Ang II; measure protein synthesis by [3H]-leucine incorporation
• In vitro smooth muscle: 1-100 nM PAMP-12 on precontracted aortic ring; compare to adrenomedullin relaxation
• Biomarker: plasma PAMP by RIA or ELISA; reference range <0.5 pmol/L in healthy adults; elevated in HF

Interactions

• Adrenomedullin: co-secreted from same proadrenomedullin precursor; complementary cardiovascular protective roles
• Norepinephrine: PAMP inhibits sympathetic NE release, providing sympatholytic cardiovascular protection
• Angiotensin II: PAMP antagonizes Ang II-driven hypertrophy and vasoconstriction via distinct non-RAAS mechanisms

Safety Profile

Endogenous peptide co-secreted with adrenomedullin. Not used therapeutically. Elevated PAMP is a risk marker in cardiovascular disease. Exogenous PAMP causes hypotension at supraphysiological doses; not suitable for clinical use without modification.

Legal & Regulatory

Research peptide; biomarker component of MR-proADM clinical assay